A multicenter randomized phase II study of the irinotecan/gemcitabine doublet versus irinotecan monotherapy in previously treated patients with extensive stage small-cell lung cancer

Lung Cancer

Volumn 65, Issue 2, 2009, Pages 187-191

  Pallis, Athanasios G ^a   Agelidou, Athina ^a   Agelaki, Sofia ^a   Varthalitis, Ioannis ^a   Pavlakou, Georgia ^a   Gerogianni, Aleka ^a   Papakotoulas, Pavlos ^a   Rapti, Ageliki ^a   Chandrinos, Vassilis ^a   Christophyllakis, Charalampos ^a   Georgoulias, Vassilis ^a  

^a Hellenic Oncology Research Group HORG   (Greece)

Author keywords

Gemcitabine; Irinotecan; SCLC; Second line therapy

Indexed keywords

ANTIBIOTIC AGENT; GEMCITABINE; IRINOTECAN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG SAFETY; EDEMA; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LUNG SMALL CELL CANCER; MALE; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; DEOXYCYTIDINE; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SMALL CELL LUNG CARCINOMA;

EID: 67449163727     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2008.11.002     Document Type: Article

References (25)

1. Jemal A., Tiwari R.C., Murray T., Ghafoor A., Samuels A., Ward E., et al. Cancer statistics. CA Cancer J Clin 54 1 (2004) 8-29
2. Jackman D.M., and Johnson B.E. Small-cell lung cancer. Lancet 366 9494 (2005) 1385-1396
3. von P.J., Schiller J.H., Shepherd F.A., Fields S.Z., Kleisbauer J.P., Chrysson N.G., et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 17 2 (1999) 658-667
4. Ettinger D.S. New drugs for chemotherapy-naive patients with extensive-disease small cell lung cancer. Semin Oncol 28 2 Suppl 4 (2001) 27-29
5. Kelly K. New chemotherapy agents for small cell lung cancer. Chest 117 4 Suppl 1 (2000) 156S-162S
6. Negoro S., Fukuoka M., Niitani H., Suzuki A., Nakabayashi T., Kimura M., et al. A phase II study of CPT-11, a camptothecin derivative, in patients with primary lung cancer. CPT-11 Cooperative Study Group. Gan To Kagaku Ryoho 18 6 (1991) 1013-1019
7. Masuda N., Fukuoka M., Kusunoki Y., Matsui K., Takifuji N., Kudoh S., et al. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 10 8 (1992) 1225-1229
8. Le Chevalier T., Ibrahim N., Chomy P., Riviere A., Monnier A., Magherini E., et al. A phase II study of irinotecan (CPT-11) in patients (pts) with small cell lung cancer (SCLC) progressing after initial response to first-line chemotherapy (CT) (Meeting abstract). Proc Am Soc Clin Oncol 16 (1997) (abstr no 1617)
9. DeVore III R.F., Blanke C., Denham C., Hainsworth J., Gralla R.J., Koletsky A.J., et al. Phase II study of Irinotecan (CPT-11) in patients with previously treated small-cell lung cancer (SCLC) (Meeting abstract). Proc Am Soc Clin Oncol 17 (1998) (abstr no 1736)
10. Noda K., Nishiwaki Y., Kawahara M., Negoro S., Sugiura T., Yokoyama A., et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346 2 (2002) 85-91
11. Hanna N., Bunn Jr. P.A., Langer C., Einhorn L., Guthrie Jr. T., Beck T., et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 24 13 (2006) 2038-2043
12. Cormier Y., Eisenhauer E., Muldal A., Gregg R., Ayoub J., Goss G., et al. Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC). A study of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 5 3 (1994) 283-285
13. Masters G.A., Declerck L., Blanke C., Sandler A., DeVore R., Miller K., et al. Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597. J Clin Oncol 21 8 (2003) 1550-1555
14. van dL I., Smit E.F., van Putten J.W., Groen H.J., Schlosser N.J., Postmus P.E., et al. Single-agent gemcitabine in patients with resistant small-cell lung cancer. Ann Oncol 12 4 (2001) 557-561
15. Agelaki S., Syrigos K., Christophylakis C., Boukovinas J., Varthalitis J., Pavlakou G., et al. A multicenter phase II study of the combination of irinotecan and gemcitabine in previously treated patients with small-cell lung cancer. Oncology 66 3 (2004) 192-196
16. Schuette W., Nagel S., Juergens S., Bork I., Wollschlaeger B., Schaedlich S., et al. Phase II trial of gemcitabine/irinotecan in refractory or relapsed small-cell lung cancer. Clin Lung Cancer 7 2 (2005) 133-137
17. Rocha-Lima C.M., Herndon J.E., Lee M.E., Atkins J.N., Mauer A., Vokes E., et al. Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and Leukemia Group B Study 39902. Ann Oncol 18 2 (2007) 331-337
18. Ohyanagi F., Horiike A., Okano Y., Satoh Y., Okumura S., Ishikawa Y., et al. Phase II trial of gemcitabine and irinotecan in previously treated patients with small-cell lung cancer. Cancer Chemother Pharmacol 61 3 (2008) 503-508
19. Castellano D., Ciruelos E., Garcia-Giron C., Lopez-Martin A., Gerrido P., Jimeno A., et al. Phase II trial of biweekly irinotecan plus gemcitabine combination in refractory or relapsed small cell lung cancer (SCLC). Proc Am Soc Clin Oncol 22 (2003) (abstr no 2710)
20. Domine M., Gonzales-Larriba J.L., Garcia Gomez R., Provencio M., Isla D., Terrasa S., et al. CPT-11-gemcitabine for refractory or relapsed small cell lung cancer (SCLC). A Spanish multicentric phase II study. Proc Am Soc Clin Oncol 22 (2003) (abstr no 2819)
21. Miller A.B., Hoogstraten B., Staquet M., and Winkler A. Reporting results of cancer treatment. Cancer 47 1 (1981) 207-214
22. Cancer Therapy Evaluation Program. Common toxicity criteria. Version 2.0. DCTD, NCI, NIH, DHHS; 1998.
23. Collet D. Modelling Survival Data in Medical Research. 3rd edn. (1994), Blackwell Scientific, Oxford
24. O'Brien M.E., Ciuleanu T.E., Tsekov H., Shparyk Y., Cucevia B., Juhasz G., et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 24 34 (2006) 5441-5447
25. Hoskins J.M., Marcuello E., Altes A., Marsh S., Maxwell T., Van Booven D.J., et al. Irinotecan pharmacogenetics: influence of pharmacodynamic genes. Clin Cancer Res 14 6 (2008) 1788-1796